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Abstract The six-minutewalking test (6MWT) hasbeenwidelyutilizedto evaluateglobalexercise capacityinpatients
with cystic ¢brosis. The aim of this study was to assess the exercise capacity by 6MWT, measuring four outcome
measures: walkdistance, oxygen saturation andpulserate during thewalk, andbreathlessnessperception after thewalk,
in a group of cystic ¢brosis adults with mild to moderate lung disease, and in healthy volunteers, as the control group.
Moreover, the studyexaminedtherelationshipbetween 6MWT outcomemeasures andpulmonary functioninpatients.
Twenty-¢ve adults (15 females, age range 18^39 years) with cystic ¢brosis and 22 healthy volunteers (14 females, age
range 20^45 years) performeda 6MWT followinga standardprotocol.Walkdistance, oxygensaturation (SpO2) andpulse
rate at rest and during walk, and breathlessness perception after walk assessed by visual analogue scale (VAS) were
measured.Cystic ¢brosis patients did notdi¡er fromhealthy volunteers inwalkdistance (626749m vs. 652746m) and
pulse rate.Patients signi¢cantlydi¡ered fromhealthy volunteers in SpO2 during thewalk (mean SpO2) (Po0?0001) and
VAS (Po0?0001).In patients, SpO2 during thewalk signi¢cantlycorrelatedwith forced expiratory volume in1sec (FEV1)
(Po0?0001), residual volume (RV) (Po0?001), resting SpO2 (base SpO2) (Po0?001), and inspiratory capacity (IC)
(Po0?01).In addition,VAS signi¢cantlycorrelatedwithresting SpO2 (Po0?01) and IC (Po0?01).Onthebasisofregression
equations by stepwise multiple regression analysis, SpO2 during walk was predicted by FEV1 (r
2=0?60) and VAS by IC
(r2=0?31), whereaswalkdistancewasnotreliablypredictedbyanyassessedvariables.This studyshowedthatcystic ¢bro-
sis adults with mild to moderate lung disease covered a normal walk distance with unimpaired cardiac adaptation, but
experienced a signi¢cant fall in oxygen saturation and an increased breathlessness perception during exercise.Resting
pulmonary functionwasrelated to oxygen saturation andbreathlessness perception duringwalk, butcontributed signif-
icantlyonly to the prediction ofoxygen saturation.We suggestthat 6MWT couldbevaluable for identifyingpatientswho
mightexperience oxygen desaturation and dyspnoea duringdemandingdaily activities.r2001Harcourt Publishers Ltd
doi:10.1053/rmed.2001.1194, available online athttp://www.idealibrary.comon
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In the last decade, the six-minute walking test (6MWT)
has beenwidely utilized to evaluate global exercise capa-
city in patients with cystic ¢brosis (CF) (1^9). Walk
distance was used to assess the bene¢cial e¡ects of lung
transplantation on exercise capacity (1,2), and it is usually
considered as a parameter-guide to list patients for the
procedure (5).Received19 April 2001, accepted in revised form 6 August 2001and
published online 22 October 2001.
Correspondence shouldbe addressed to:Dr. AlfredoChetta, Istituto di
Malattie Respiratorie, Azienda Ospedaliera Universitaria di Parma,
Viale G.Rasori,10-43100, Parma, Italy.Fax: +39 0521292 615; E-mail:
chetta@unipr.itIn addition, in patients with CF, the walk distance was
highly reproducible (4,8) and related to maximum work-
load (4) and maximum oxygen uptake (3,4) measured
during a standardized maximum incremental exercise
testing on a cycle ergometer. Thus, the 6MWT has also
been proposed as a simple and reliable test for the
periodic evaluation of CF patients’ exercise programmes
(4). Furthermore, the exercise performed during the
6MWT is more relevant to the everyday lives of patients
than that performed during other forms of exercise test,
such as treadmill or cycle ergometer, and may more
accurately re£ect what occurs during demanding daily
activities.
However, up to now, no 6MWT studies have com-
pared outcomemeasures of CF patients to those of age
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has been speci¢cally addressed to assess walk tolerance
in adults su¡ering from CF, nor to evaluate the relation-
shipsbetween outcomemeasures of 6MWTandpulmon-
ary function.The aim of thepresent study was therefore
to assess the exercise capacity by 6MWT, measuring
four outcome measures: walk distance, oxygen satura-
tion and pulse rate during the walk, and breathlessness
perception after the walk, in a group of CF adults with
mild tomoderate lungdisease, and in healthy volunteers,
as a control group. Moreover, the study examined the
relationship between 6MWT outcome measures and
pulmonary function in CF patients.
METHODS
Subjects
We studied 25 adults (15 females, age range18^39 years),
diagnosed as having CF by the sweat test. Severity of
disease was evaluated by a modi¢ed version of the
Schwachman scoring system (10), which is a 0^100 score,
based on the general activity of the patient, physical
examination, nutritional status and chest X-ray.We only
included non-smoking patients in clinically stable
conditions, de¢ned as an absence of re-exacerbation for
at least 4 weeks and as therapeutic stability. Moreover,
no patients included in the study had histories of
concomitant anaemia or locomotion problems, nor did
any patients need current oxygen therapy or had a
resting oxygen saturation (SpO2, %) less than 90%.
As a control group we studied 22 healthy volunteers
(14 females, age range 20^45 years).None of the healthy
subjects had history of respiratory disorders and they
were lifetime non-smokers. All subjects gave informed
consent to participate in the study.
Lung function test
Pulmonary function was measured by a £ow-sensing
spirometer and a body pletismograph connected to a
computer for data analysis (Vmax 22 and 6200, Sensor
Medics,Yorba Linda,U.S.A.). Baseline total lung capacity
(TLC), residualvolume (RV),RV/TLCratio, forcedexpira-
tory volume in 1sec (FEV1), forced vital capacity (FVC),
FEV1/FVC ratio and inspiratory capacity (IC) were re-
corded. Carbon monoxide transfer capacity (TLCO) was
measured by the single breath method and considered
valid only if the inspiratory volume was at least 90% of
FVC. At least three measurements were made for each
lung function variable to ensure reproducibility. Pre-
dicted values of lung volumes and expiratory £ows as
well as carbon monoxide transfer capacity were
obtained from regression equations by Quanjer et al. (11)
and Coteset al. (12), respectively.Six-minutewalk test
After lung function testing, patients and volunteers per-
formed two 6MWTs according to a standard protocol
(13). All subjects received the same instructions before
the walk and were encouraged by the investigator who
repeated set phrases every 30 sec during the walk. The
6MWTs were symptom limited, so patients were
allowed to stop if necessary, though they were in-
structed to resumewalking as soon as possible.The sec-
ond 6MWTwas performed in the same manner as the
¢rst, following a rest of at least 60min.
The walk distance covered during the test was
recorded in meters. Results from the second walk
only were used for analysis to allow for any learning
e¡ect (14).
Before and immediately after 6MWT, patients and
volunteers rated the magnitude of their perceived
breathlessness on an interval scale, which was a
100-mm horizontal visual analogue scale (15). The visual
analogue scale (VAS) consisted of a horizontal
ruler without any mark on the patient’s side with the
words ‘not at all breathless’ and ‘extremely breathless’
on the left and right end, respectively. The subject had
to indicate his breathlessness perception at themoment
of the assessment, by moving a marker along the
ruler. Breathlessness perception ratings were expressed
in mm from 0 to 100 and corresponded to the distance
of the marker from the left end of the visual analogue
scale.
Oximetry andpulse rate
The SpO2 and the pulse rate (PR, bpm) were
continuously monitored from 5min before the walk
until the test completion, as well as 5min after comple-
tion, or until recovery of the baseline value by using a
light weight (0.3 kg) portable pulse oximeter
(Healthdyne, Model 920M, Marietta, GA, U.S.A.).
This device was carried by each subject with a shoulder
strap and a ¢nger probe and was applied to the non-
dominant hand. The oxygen saturation and heart rate
readings were recorded in the oximeter memory every
10 sec.
For each subject, the resting SpO2 values (base SpO2,
%), such as the average of the SpO2 readings taken be-
fore the walk, and the mean saturation recorded during
thewalk (mean SpO2, %) were noted.
The resting PR values (base PR, bpm), such as the
average of the PR readings taken before the walk, the
mean pulse rate recorded during the walk (mean
PR, bpm) and the maximum pulse rate sustained for
more than 10 sec (max PR, bpm) during the walk
were also noted. The predicted maximum pulse rate
was calculated by the following equation:
210ÿ0.66 age (16).
TABLE 1. Characteristics of 25 patients with cystic
¢brosis and 22 healthy volunteers
Cystic ¢brosis
patients
Healthy
volunteers
Age (years) 2575 2676
Gender (F/M) 15/10 14/8
BMI (kgmÿ2) 2172 2372
FEV1 (% of pred) 69723 121716**
FVC (% of pred) 85720 124717**
RV (% of pred) 162752 82727***
TLC (% of pred) 107715 113711
IC (l) 2?770?9 3?370?9*
TLCO (% of pred) 82715 105713**
Base SpO2 (%) 9671 9871**
Base PR (bpm) 87714 7676**
Values are expressed asmean7SD.
*Po0?05, **Po0?001.
TABLE 2. Di¡erencesinoutcomemeasureof six-minute
walking test between 25 patientswith cystic ¢brosis and
22 healthy volunteers
Cystic ¢brosis
patients
Healthy
volunteers
Walkdistance (m) 626749 652746
Mean PR (bpm) 121721 114718
Max PR (bpm) 143718 136717
Max PR (% pred) 74710 7178
Mean SpO2 (%) 9274 9771**
VAS (mm) 64724 27719**
Values are expressed as (mean7SD).
**Po0.001.
FIG. 1. Time course of mean pulse rate during walk (mean PR)
in 25 patients with cystic ¢brosis (*) and in 22 healthy volun-
teers (*).
988 RESPIRATORYMEDICINEStatistical analysis
All pulmonary function test results are expressed as per
cent of predicted value or as absolute value.The patients
were also studied with reference to mean SpO2 values
and divided in two groups, choosing one reference point:
90 % or less and more than 90%. Data are reported as
mean7standard deviation (SD) and di¡erences in numer-
ical data betweengroupswere determinedbyunpaired t-
test. Di¡erences in qualitative data were analysed by
Fisher exact test. Also, relationships were estimated by
the Pearson correlation coe⁄cient (r).
We chose FEV165% and base SpO296% as values
for detecting a mean SpO290%. Sensitivity, speci¢city
and predictive values for FEV1 and base SpO2 to deter-
mine mean SpO2 were calculated by standard methods
(17). Stepwise multiple regression analysis was used to
determine the best predictor variables for the depen-
dent variables walk distance, breathlessness perception
ratings after walk, mean SpO2 andmean PR. Percentage
of total variance in the dependent variable, accounted
for by the predictors variables is expressed as the
adjusted square of the multiple correlation coe⁄cient
(r2). A P-value of less than 0?05 was taken as signi¢cant,
however, only those results with a signi¢cance level of
less than 0?01are given for correlations.
RESULTS
Personal details of patients and healthy volunteers are
reported inTable 1. Patients had CF of varying severity.
The mean Schwachman score was 67713 (range
40^90). All CF patients were able to complete a 6MWT.
There were no signi¢cant di¡erences between
patients and healthy subjects when age, sex and BMI
were considered. Patients di¡ered from healthy volun-
teers in FEV1 (Po0?001), FVC (Po0?001), RV (Po0?001),
IC (Po0?05), TLCO (Po0?001), base SpO2 (Po0?001) and
base PR (Po0?001) (Table1).
The walk distance was 626749m, ranging from 500
to 725m, and 652746m, ranging from 544 to 738m, in
patients and healthy volunteers, respectively (Table 2).
There was no signi¢cant di¡erence between males and
females in patients (646751m and 613744m) and in
healthy volunteers (670762m and 641733m). CF
patients and healthy volunteers did not also di¡er in
mean PRvalues and inmax PR (Table 2).The time course
ofmean PR during 6MWTwas also similar in CF patients
and controls (Fig.1).
CF patients signi¢cantly di¡ered from healthy volun-
teers in mean SpO2 (Po0?0001) and VAS (Po0?0001)
(Table 2). Furthermore, a mean SpO2 90% occurred in
nine out of 25 patients. In patients with mean
SpO290%,FEV1,RVandbaseSpO2 signi¢cantly di¡ered,
when compared to those of patients with mean
SpO2490%. However, the walk distance covered by
TABLE 3. FEV1 and base SpO2 as screening parameters
fordetecting amean SpO2r90% in 25 patientswithcys-
tic ¢brosis
Mean SpO2r90%
Sensitivity
FEV1r65% pred 89%
Base SpO2r96% 89%
Speci¢city
FEV1r65% pred 94%
Base SpO2r96% 87%
Positive predictedvalue
FEV1r65% pred 94%
Base SpO2r96% 82%
Negative predictedvalue
FEV1r65% pred 89%
Base SpO2r96% 100%
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of patients with mean SpO2490% (620764m vs.
629739m). Furthermore, theVASmeasured in patients
withmeanSpO290%didnotdi¡er from thatof patients
withmean SpO2490% (77715mm vs. 56726mm).
In CF patients, mean SpO2 signi¢cantly correlated
with FEV1 (r=0.69, Po0?0001), RV (r=ÿ0?68, Po0?001),
Base SpO2 (r=0?68, Po0?001), and IC (r=0?55,
Po0?01) (Fig. 2). In addition,VAS signi¢cantly correlated
with Base SpO2 (r=ÿ0?58, Po0?01) and IC (r=ÿ0?52,
Po0?01).
Results of sensitivity, speci¢city and predictive value
calculations for FEV165% andbase SpO296% as values
for detecting ameanSpO290% arepresented inTable 3.
The regression equation generated by stepwise multiple
regression analysis for mean SpO2 included FEV1: mean
SpO2 (%)=83?7+0?12 (FEV1); r
2=0?60.
Moreover, ICwas chosen bymultiple regression analy-
sis as themain predictor variable forVAS.Theregression
equation for VAS was: VAS (mm)=107.3ÿ15.6 (IC);
(r2=0?31).
Lastly, multiple regression analysis for walk distance
could not account for more than 20% of the total var-
iance (r2=0?19), themain predictor variable being IC.FIG. 2. Relationships betweenmean oxygen saturation during wa
turation (base SpO2) (d) in 25 patientswith cystic ¢brosis. r=PearsoDiscussion
Our study showed that CF patients with mild tomoder-
ate lung disease, when compared to controls, did not dif-
fer inwalkdistance and in pulse rate during thewalk, butlk (mean SpO2) and FEV1 (a), IC (b),RV (c), and resting oxygen sa-
n correlation coe⁄cient.
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perception during thewalk.Furthermore, in CFpatients
pulmonary function was related to oxygen saturation
and breathlessness perception during walk, but contrib-
uted signi¢cantly only to predict oxygen saturation.
The 6MWT is a simple and non-expensive test that
can provide a global evaluation of exercise capacity in
patientswith respiratory disability and thewalk distance
is themost popular outcomemeasure (18). Interestingly,
we found that thewalkdistance coveredby young adults
with CF and ventilatory impairment was the same as
that covered by age- and sex-matched healthy volun-
teers. Maximum exercise capacity in patients with CF
depends on the severity of the impairment in lung func-
tion (19,20), however, 6MWT canbe considered as an en-
durance, submaximal exercise test, since it demands the
ability to sustain the exercise, rather than the capacity
for maximum exercise.Our ¢ndings are consistent with
a previous report by Freeman et al., who demonstrated
in adultswith cystic ¢brosis a normal tolerance to endur-
ance exercise test, de¢ned as the duration of exercise at
80% of each individuals maximum oxygen uptake (21).
Moreover, in the present study, the walk distance does
not seem tobe signi¢cantly a¡ectedby lung function lim-
itation in CF patients, since it was only barely predicted
by the inspiratory capacity. These results are in agree-
ment with those by Foglio et al. (22), who recently de-
monstrated that in adults with chronically stable airway
obstruction the walk distance was poorly predicted by
baseline lung functionmeasures. Furthermore, Freeman
etal. (21) didnot ¢nd any signi¢cantrelationship between
the endurance times of submaximal exercise andbaseline
lung function. Home exercise training programs, cur-
rently followed by patients in their maintenance treat-
ment could explain the tolerance to the sub maximal
exercise in CF. In fact, home exercise training programs
are e¡ective for improving physical performance and to
decrease limitation in activities of daily living in
CF patients, even in those with moderate to severe
pulmonary impairment (23).
We found that patients and healthy controls per-
formed the same e¡ort not only in terms of walk dis-
tance, but also in terms of cardiac function. At baseline,
CF patients showed a pulse rate higher than that of con-
trols. A mild to moderate resting thachycardia is a com-
mon feature in CF (24,25) and may represent a right
ventricular dysfunction (25). During walk, CF patients
experienced a change in pulse rate, as percent of base-
line, similar to that of controls (29% vs. 33%). In addition,
similarly in patients and controls, pulse rate progres-
sively increased during the ¢rst 2min of the walk, then
it reached a plateau, which lasted for the remaining
4min (Fig.1).Taken together, these ¢ndings showed that
6MWT induced a submaximal e¡ortwith an appropriate
cardiac response in adults with CF. These results are in
agreement with a previous report in children with CF,who showed a pulse rate, equal to a 25% change com-
pared to baseline, while performing 6MWT (8). Interest-
ingly, in patients a¡ected by CF, irrespective of the
severity of lung disease, the heart rate responsewas ap-
propriate for work amount, also during a progressive in-
cremental cycle ergometer test (19). Furthermore, even
in patients with severe lung involvement and elevated
resting heart rate, the cardiovascular response to exer-
cise was normal (19).On the whole, data on cardiac re-
sponse both to sub maximal and maximal e¡ort
support the view that in CF there is no cardiac limitation
to exercise.
Although CF patients had a normal performance in
terms of walkdistance andpulse rate, they showed a sig-
ni¢cant fall in oxygen saturation during walk, when com-
pared to the control group. Oxygen saturation during
walk was strictly related to airway obstruction and
hyperin£ation, as well as to the baseline oxygen satu-
ration. More speci¢cally, we found that the saturation
during walk could be highly predicted by baseline FEV1,
which can account for 60% of the total variance. More-
over, the fall in oxygen saturation during walk was clini-
cally signi¢cant in a third of CF patients, since in these
patients the oxygen saturation reached or exceeded the
value of 90%.Our study also showed that patients with a
FEV1o65% predicted or with a resting oxygen saturatio-
no96% are highly likely to develop an oxygen saturation
during walk less than or equal to 90%. This ¢nding is in
agreement to a previous endurance submaximal exercise
study, that suggested that patients with a FEV1o60%
predicted or with a resting oxygen saturationo95% are
vulnerable for exercise oxygen desaturation (21). In this
study, patients had mild to moderate impairment in dif-
fusing capacity and did not show any relationship be-
tween resting TLCO and oxygen saturation during walk.
Despite the airway obstruction and hyperin£ation, CF
patients had a relative preservation of di¡using capacity,
measured by the single breath method (26), and mea-
surements of TLCO were unreliable for predicting oxygen
desaturation induced by submaximal exercise (21). In CF
patients, ventilation^perfusion mismatch and alveolar
hypoventilation proved to be the physiological causes of
the arterial oxygen desaturation during maximal exer-
cise (19).
In this study, CF patients had a signi¢cant increase in
ratings on the visual analogue scale after walk when
compared to controls, however the induced breathless-
ness couldnotbereliablypredictedby anyoutcomemea-
sure of 6MWTor any variables of resting lung function.
Therefore, our results support the view that the under-
lyingmechanisms of exertion dyspnea, a disabling symp-
tom in CF, are elusive, and that subjectivity is inherently
involved in the symptom. In this regard, to date, previous
reports inCFpatientsregarding the exertionbreathless-
ness perception reveal various results. De Jong et al.
showed that though dyspnoea could in£uence exercise
SIX-MINUTEWALKTEST INADULTSWITHCYSTICFIBROSIS 991capacity, breathlessness perception score showed a large
inter-individual variation, not strongly related to pul-
monary function (27). Additionally, other studies
showed signi¢cant relationships between exertion dys-
pnoea score and quality of life (28) or exercise intensity
degree (29), butdid notreport anyrelationships to base-
line lung function.
In summary, we showed that in CF adults withmild to
moderate lung disease, walk distance is normal and car-
diac adaptation towalk is unimpaired.However, patients
experienced a signi¢cant fall in oxygen saturation and an
increased breathlessness perception during exercise.
Our ¢ndings suggest that 6MWT can be valuable for
identifying patients who might experience oxygen desa-
turation and dyspnoea during demanding daily activities.
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